A single center, open-label, two-period, non-randomized, paired-design study to compare steady-state plasma levels following switch from a 10 mg/ml treprostinil formulation to a 20 mg/ml treprostinil formulation in patients with pulmonary arterial hypertension (PAH)
Latest Information Update: 31 Mar 2022
At a glance
- Drugs Treprostinil (Primary)
- Indications Pulmonary arterial hypertension
- Focus Pharmacokinetics
- Sponsors AOP Orphan Pharmaceuticals AG
- 30 Mar 2022 Status changed from recruiting to completed.
- 08 Dec 2021 New trial record